Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta

Scientists Without Borders
The New York Academy of Sciences held its kickoff last night of Scientists Without Borders. “It’s a Match.com for organizations and resources focused on helping the developing world,” said NYAS president Ellis Rubinstein.
The initiative so far consists of a just-launched wiki—and, as such, leaves a little to be desired in terms of content. But the tools are all there, explained the site’s developer, urging everyone in the audience who had resource supplies or demands to sign up, make connections, and work toward new solutions for dire problems such as poverty, disease, hunger, and climate change in sub-Saharan Africa and other places.
A Kiva for scientists and technical experts? Only time will tell. But the technology certainly has the pharmaceutical industry’s support. Merck kicked in seed-funding for the project, and 10 other pharma companies (as well as mosquito-net producer Vestergaard Frandsen) covered the rest.
(To check out the list of pharma supporters, click here.)
Keynoting the event was leading global economic advisor—and passionate advocate for third world development—Dr. Jeffrey Sachs. (I slipped him a Pharm Exec, and he promised me an interview.) Joining Sachs were notable speakers including International AIDS Vaccine Initiative president Dr. Seth Berkley. But what I found most interesting was the mix of participants in the audience.
There were diplomats (“I can only announce the names of director consulates, there’s too many associate consulates here to announce,†apologized Rubinstein), business leaders, nonprofits representatives, and members of the drug industry. The table seating encouraged cross-functional networking using ice breakers—I found myself beating a djembe drum next to a wealth manager from Merrill Lynch and Peter Farina, head of a new R&D nonprofit Developing World Cures, who previously lead the Viramune R&D effort at Boehringer Ingelheim.
All that mixing and matching smacked of new models said a tablemate from Sanofi Aventis—and that’s something every company is now looking for. While the power of the Scientists Without Borders database will depend on the commitment of its users, certainly the intention of the project, and the collaborative spirit of the kickoff, showcase a new path toward getting aid on the ground to the people who need it the most.